Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Lymphoma, Large B-Cell, Diffuse 20Lymphoma, Mantle-Cell 13Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell, Marginal Zone 7Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, Follicular 6Lymphoma, B-Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Blast Crisis 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, AIDS-Related 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Chronic-Phase 1Hematopoietic and Lymphoid System Neoplasm 1Composite Lymphoma 1Classic Follicular Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Rituximab 7Vemurafenib 4Cyclophosphamide 4Cladribine 4Specimen Handling 3Biopsy 3obinutuzumab 2ibrutinib 2fludarabine phosphate 2fludarabine 2binimetinib 2Diphenhydramine 2Dexamethasone 2Calcium Dobesilate 2CT-P10 2Acetaminophen 2venetoclax 1tovorafenib 1polatuzumab vedotin 1pembrolizumab 1immunotoxin HA22 1encorafenib 1dexamethasone acetate 1dexamethasone 21-phosphate 1brexucabtagene autoleucel 1auricularum 1acalabrutinib 1Whole-Body Irradiation 1Valganciclovir 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × CT-P10 × 1 year × Clear all
NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT00412594 2025-12-22

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
150 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡